Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
127 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape. H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 6, 5, 18 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 2, 1, 1 and 3 molecules, respectively. Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Influenza A Virus, H3N2 Subtype Infections - Overview 8 Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 18 Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment 19 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development 27 AbbVie Inc 27 Adimmune Corp 28 AIMM Therapeutics BV 28 Aphios Corp 29 BioCryst Pharmaceuticals Inc 29 BiondVax Pharmaceuticals Ltd 30 Cadila Healthcare Ltd 30 Celltrion Inc 31 FluGen Inc 31 Glide Pharmaceutical Technologies Ltd 32 Inovio Pharmaceuticals Inc 32 Jiangsu Kanion Pharmaceutical Co Ltd 33 Johnson & Johnson 33 Medicago Inc 34 MedImmune LLC 34 Mucosis BV 35 NanoViricides Inc 35 Novavax Inc 36 OPKO Health Inc 36 Protein Sciences Corp 37 Sanofi Pasteur SA 38 Sarepta Therapeutics Inc 38 SK Chemicals Co Ltd 39 Takeda Pharmaceutical Company Ltd 39 VBI Vaccines Inc 40 Visterra Inc 40 Influenza A Virus, H3N2 Subtype Infections - Drug Profiles 41 APP-0205 - Drug Profile 41 APP-309 - Drug Profile 42 Aspidasept - Drug Profile 43 AT-0701 - Drug Profile 44 AV-5075S - Drug Profile 45 AV-5080 - Drug Profile 46 C-05 - Drug Profile 47 cetylpyridinium chloride - Drug Profile 48 CR-8043 - Drug Profile 49 CTP-27 - Drug Profile 50 Fluad (quadrivalent) - Drug Profile 51 Gamma-Flu - Drug Profile 52 influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile 53 influenza [strain A/H3N2] vaccine - Drug Profile 54 influenza [strain A/H3N2] vaccine - Drug Profile 55 influenza [strain A/H3N2] vaccine - Drug Profile 56 influenza [strain A/H3N2v] vaccine - Drug Profile 57 influenza [strain A/H3N2v] vaccine - Drug Profile 58 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 59 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 60 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 61 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 62 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 63 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 64 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 67 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 68 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 69 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 70 influenza [strains A/H1N1 + A/H3N2 + B] (split virion) vaccine - Drug Profile 71 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 72 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 76 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 77 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 78 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 79 influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile 80 influenza [strains A/H3N2 + A/H1N1] vaccine - Drug Profile 81 M-001 - Drug Profile 82 NBP-607 - Drug Profile 88 NEO-8877 - Drug Profile 89 NVINF-1 - Drug Profile 90 NVINF-2 - Drug Profile 95 Peptides for Influenza Infections - Drug Profile 98 peramivir - Drug Profile 99 pertussis [strain BPZE1] vaccine - Drug Profile 101 pimodivir hydrochloride - Drug Profile 103 PNSIA-28 - Drug Profile 106 radavirsen - Drug Profile 107 REDEE FLU - Drug Profile 109 Small Molecules for RSV and Influenza A Infections - Drug Profile 110 Small Molecules to Inhibit Neuraminidase for Influenza A Virus Infections - Drug Profile 111 VIS-410 - Drug Profile 112 Influenza A Virus, H3N2 Subtype Infections - Dormant Projects 115 Influenza A Virus, H3N2 Subtype Infections - Discontinued Products 116 Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones 117 Featured News & Press Releases 117 Appendix 123 Methodology 123 Coverage 123 Secondary Research 123 Primary Research 123 Expert Panel Validation 123 Contact Us 123 Disclaimer 124
List of Tables
Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Adimmune Corp, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics BV, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by BioCryst Pharmaceuticals Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Cadila Healthcare Ltd, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Ltd, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Protein Sciences Corp, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra Inc, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H2 2017 Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
